Breaking News

Bora Expands CDMO Capabilities with Acquisition of TWi Pharmaceuticals

Adds two manufacturing facilities and strengthens service offerings in formulation development, sterile ophthalmic, and niche manufacturing technologies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fast-growing contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, has completed the acquisition of TWi Pharmaceutical, a technology-based company specializing in development and commercialization of niche generic drugs. Acquiring TWi Pharmaceuticals adds two manufacturing facilities and will significantly boost Bora’s service offerings in key areas, such as formulation development, sterile ophthalmic, and niche manufacturing technologies. “The acquisition of TW...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters